PAP
CYTK icon

Persistent Asset Partners’s Cytokinetics CYTK Stock Holding History

Persistent Asset Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$455K Buy
+5,346
New +$384K 0.14% 121
2026
Q1 		– Sell
-3,214
Closed -$204K – 368
2025
Q4 		$204K Buy
+3,214
New +$200K 0.09% 211
2025
Q2 		– Sell
-4,576
Closed -$184K – 197
2025
Q1 		$184K Buy
+4,576
New +$210K 0.15% 101

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Persistent Asset Partners's CYTK Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in Cytokinetics (CYTK) in Q2 2026: 5,346 shares worth $455K. The stake represents 0.14% of the portfolio and ranks #121 among its holdings. This is a return to the name: Persistent Asset Partners previously reported a position in CYTK as recently as Q4 2025.

Persistent Asset Partners first reported a position in CYTK in Q1 2025 and has held it in 3 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Persistent Asset Partners held 5,346 shares of Cytokinetics worth $455K as of Q2 2026.
  • Cytokinetics was a new Persistent Asset Partners position in Q2 2026.
  • Cytokinetics made up 0.14% of Persistent Asset Partners's portfolio in Q2 2026, its #121 holding.
  • Persistent Asset Partners first reported a position in Cytokinetics in Q1 2025 and has held it in 3 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.